INCY News and Press, Incyte Corporation From 08/01/21

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe; now holds 4...

You don't need to have the bank account of Warren Buffett to begin investing in stocks. Nor do you need to invest solely in companies with ultra-high stock prices like Amazon , which is trading at roughly $3,629 a share as of this writing. Investing on a budget can be profitable, too, a...

The FDA has broadened the Emergency Use Authorization ("EUA") for Eli Lilly (LLY +0.3%) and Incyte's (INCY +0.5%) Olumiant (barictinib) to allow with or without use with Gilead's (GILD -0.2%) Veklury (remdesivir). Before, baricitinib could only be used in combination with remdesivir. The...

Gainers: [[NRXP]] +10.1%. [[PDD]] +6.6%. [[TLSA]] +6.3%. [[AFMD]] +4.4%. [[UXIN]] +3.8%.Losers: [[ACOR]] -3.8%. [[IPA]] -2.8%. [[SNCR]] -2.5%. [[PRVB]] -2.3%. [[INCY]] -3.3%. For further details see: NRXP, PDD, ACOR and IPA among after-hours movers

Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, for the treatment of adult patients with local...

Check Out These Top Biotech Stocks In The Stock Market Now Biotech stocks have remained relevant in the stock market even in challenging times. This is because each stage and interim progress along the way can act as a catalyst for biotech stocks . Any positive update can le...

Phase 3 REACH3 data show that ruxolitinib (Jakafi ® ) significantly improved overall response rate (ORR) at Week 24 (49.7% vs. 25.6%) with a higher best overall response rate (76.4% vs. 60.4%) vs. best available therapy among patients with steroid-refractory/dependent c...

BriaCell Therapeutics (BCTX) announces the open recruitment and enrollment of their collaborative clinical study with Incyte (INCY).The Phase I/IIa combination study is designed to evaluate BriaCell’s lead candidate, Bria-IMT, with Incyte’s checkpoint inhibitor, retifanlimab, an...

Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holding...

Innovent Biologics (IVBIY) announces that the National Medical Products Administration ((NMPA)) of China has accepted the New Drug Application ((NDA)) for FGFR1/2/3 inhibitor (pemigatinib) for the treatment of certain adults with cholangiocarcinoma.Pemigatinib looks to treat pa...